{
  "id": 193505,
  "name": "ASTRAZENECA PHARMACEUTICALS LP",
  "slug": "astrazeneca-pharmaceuticals-lp",
  "state": "DE",
  "description": "Biopharmaceutical Company.",
  "totalSpending": 1830000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 200000
    },
    {
      "year": 2019,
      "income": 150000
    },
    {
      "year": 2020,
      "income": 120000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 320000
    },
    {
      "year": 2024,
      "income": 240000
    },
    {
      "year": 2025,
      "income": 320000
    }
  ],
  "firms": [
    "W STRATEGIES, LLC"
  ],
  "lobbyists": [
    "DARREN WILLCOX"
  ],
  "issues": [
    "BUD",
    "MMM",
    "HCR",
    "TRD",
    "SCI",
    null
  ],
  "sampleDescriptions": [
    "H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.\n\nH.R.1625: Consolidated Appropriations Act, 2018.",
    "H.R.1834: Cancer Care Payment Reform Act of 2017.\n\nEducation about innovative contracting and value based payments.\n\nSynchronization and Nonadherence Correction (SYNC) Act.\n\nH.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.",
    "Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.\n\nCDC Recommendations about flu treatments.",
    "H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision.",
    "Education about innovative contracting and value based payments.\n\nEducation about the 340(b) drug discount program including the CMS 340(b) CMP Rule.",
    "Education about innovative contracting and value based payments.",
    "H.R.6642: \"to sunset the limit on maximum rebate amount for single source drugs\".",
    "H.R.107: to sunset the limit on maximum rebate amount for single source drugs.\n\nRegulatory and legislative proposals in the Administrations Blueprint.\n\nH.R.2113:  Prescription Drug STAR Act.",
    "H.R.107: to sunset the limit on maximum rebate amount for single source drugs.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nRegulatory and legislative proposals in the Administrations Blueprint.\n\nH.R.2113: Prescription Drug STAR Act / H.R.2296: FAIR Drug Pricing Act.\n\nFY 2020 Continuing Resolution.",
    "H.R.107: to sunset the limit on maximum rebate amount for single source drugs.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nH.R.19: Lower Costs, More Cures Act of 2019.\n\nRegulatory and legislative proposals in the Administrations Blueprint.",
    "Education around COVID-19 vaccines.",
    "Education around COVID-19 vaccines. \n\nEducation about the 340(b) program.",
    "H.R.107: to sunset the limit on the maximum rebate amount for single source drugs.  \n\nH.R.4996: Helping MOMS Act of 2020.",
    "Education around COVID-19 vaccines.\nH.R.1319: American Rescue Plan Act of 2021.",
    "Issues related to COVID-19 vaccines and TRIPS at WTO.",
    "H.R.3: Elijah E. Cummings Lower Drug Costs Now Act.\n\nH.R.19: Lower Costs, More Cures Act of 2021.",
    "S.1260: Endless Frontier Act",
    "FY'22 Budget Reconciliation including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. And H.R.19. Lower Costs, More Cures Act of 2021.",
    "H.R.5376: Build Back Better Act including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, and H.R.19. Lower Costs, More Cures Act of 2021.",
    "Reauthorization of the Prescription Drug User Fee Act and related issues. H.R.2471: Consolidated Appropriations Act, 2022. H.R.7007: COVID Supplemental Appropriations Act, 2022."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 60,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 228750,
  "peakYear": 2023,
  "lobbyistCount": 1,
  "firmCount": 1,
  "issueCount": 5,
  "industry": "healthcare"
}